Q-omics provides the consensus-scored ME2 profile across patient tissues and cancer cell-line models. ME2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ME2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ME2 protein abundance shows 23,063 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, COAD, and BRCA as cancer lineages where ME2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ME2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ME2 survival associations across molecular data types. ME2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ME2 RNA expression–survival associations across cancer types. High ME2 expression shows unfavorable associations in UVM, LIHC, ACC and KICH, but favorable associations in COAD and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for ME2 RNA expression.
This table summarizes ME2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ME2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ME2 shows lower tumor expression in COAD, THCA and READ and higher tumor expression in HNSC, KIRC and LIHC. The COAD box plot shows higher ME2 RNA expression in normal versus tumor tissue (log2 FC = −1.043, t-test p < 0.001).
This table shows molecular features associated with ME2 in patient tissues and cancer cell lines. In patient samples, ME2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ME2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
